To evaluate the prognostic and clinicopathological significance of PTTG1 expression in solid tumors through a comprehensive meta-analysis.
Approach:
Search Strategy: A comprehensive search of PubMed, EMBASE, and Web of Science was performed to identify eligible studies until July 20, 2025.
Inclusion and Exclusion Criteria: Studies were included if they reported on cancer patients, the prognostic value of PTTG1, and survival outcomes, while excluding irrelevant topics and incomplete survival data.
Data Extraction and Quality Assessment: Data was independently extracted by two investigators, and the quality of studies was assessed using the Newcastle-Ottawa Scale.
Statistical Analysis: Stata Software 12.0 was used to calculate pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs).
Key Findings:
Patients with high PTTG1 expression had poorer overall survival (OS) (HR: 1.85, 95% CI: 1.55-2.20) and disease-free survival/recurrence-free survival (DFS/RFS) (HR: 3.48, 95% CI: 1.81-6.70).
Subgroup analysis showed that high PTTG1 expression was mainly associated with worse OS in renal cell carcinoma, non-small cell lung cancer, breast cancer, esophageal squamous cell carcinoma, and laryngeal cancer.
High PTTG1 expression was significantly associated with advanced tumor stage, T stage, lymphatic invasion, and metastasis.
Interpretation:
PTTG1 may serve as a prognostic indicator in specific cancers.
Limitations:
Some studies reported inconsistent findings regarding PTTG1's prognostic value.
Methodological limitations and sample size issues in individual studies may affect reliability.
Conclusion:
PTTG1 may serve as a prognostic indicator in specific cancers.
